Health care stocks were rising Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.6%.
The iShares Biotechnology ETF (IBB) added 1.1%.
In corporate news, Novo Nordisk (NVO) said it launched a direct-to-patient delivery option that offers patients all dose strengths of Wegovy at a reduced cost. Novo shares gained 3.4%.
Amgen (AMGN) has started two phase 3 trials for its obesity drug MariTide, the company's Head of Research and Development, Jay Bradner, said Wednesday at an investor conference. Amgen shares rose 1.4%.
Merck (MRK) is facing a patent dispute that threatens its plans to sell a new version of Keytruda, its top-selling cancer drug, the Wall Street Journal reported. Merck shares were fractionally higher.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。